Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders

Core Insights - Bionano Laboratories announced the establishment of a new Category I CPT code for optical genome mapping (OGM) in cytogenomic genome-wide analysis, effective January 1, 2026, which is crucial for reimbursement from third-party payers [1][2][3] Group 1: CPT Code Significance - The new CPT code is the second issued for OGM, following code 81195 established in 2024 for hematological malignancies, indicating that OGM has met rigorous Category I standards [2] - The approval of this CPT code is expected to enhance the awareness and utility of OGM in both oncology and clinical genetic testing communities [3] Group 2: Bionano Laboratories' Offerings - Bionano Laboratories provides CLIA-certified laboratory developed tests (LDTs) utilizing OGM technology to detect structural and copy number variations related to genetic disorders [1][4] - The OGM-Dx Postnatal and Prenatal Whole Genome SV tests are designed to detect all classes of structural variants traditionally tested by multiple methods, showcasing the advantages of OGM over legacy methods [3] Group 3: Company Overview - Bionano Genomics aims to transform genome analysis through OGM solutions, diagnostic services, and software, catering to applications across basic, translational, and clinical research [5]